12:00 AM
 | 
Nov 11, 2013
 |  BC Week In Review  |  Clinical News  |  Regulatory

Aptiom eslicarbazepine acetate regulatory update

FDA approved an NDA from Dainippon's Sunovion Pharmaceuticals Inc. subsidiary for Aptiom eslicarbazepine as an add-on therapy to treat partial-onset seizures in adults with epilepsy. The company plans to launch the drug in the...

Read the full 146 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >